TP53 and acute myeloid leukemia: When co-incubated with anti-CD33 CAR T-cells at various effector-to-target (E:T) ratios (Fig. 1A), we consistently observed significantly less killing of MOLM13-TP53 AML cells with knockout (MOLM13-TP53−/−) or missense mutant (MOLM13-TP53missense/−) alleles as compared to MOLM13-TP53 AML cells with wild-type TP53 (MOLM13-TP53+/+) at early (d1) or later (d6) time points (Fig. 1C–F).